3Q'25 vs. 3Q'24 Results Sales: € 9.328 Bn (0.0% vs. +2.3% BS(e) and n/a consensus); EBIT: € 2.053 Bn (+2.0% vs. +12.8% BS(e) and +4.1% consensus); 9M'25 vs. 9M'24 Results Sales: € 25.234 Bn (+4.9% vs. +5.8% BS(e) and n/a consensus); EBIT: € 5.852 Bn (+76.2% vs. +24.9% BS(e) and +19.6% consensus);
Rdos. 3T'25 vs 3T'24: Ventas: 9.328 M euros (0,0% vs +2,3% BS(e) y n/a consenso); EBIT: 2.053 M euros (+2,0% vs +12,8% BS(e) y +4,1% consenso). Rdos. 9meses'25 vs 9meses'24: Ventas: 25.234 M euros (+4,9% vs +5,8% BS(e) y n/a consenso); EBIT: 5.852 M euros (+76,2% vs +24,9% BS(e) y +19,6% consenso).
NEWS SUMMARY: ACS, AMADEUS, CELLNEX, IAG, SACYR. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Doubts persist With the results campaign entering the final stretch, the main European indices closed with losses, with the IBEX standing out as the best performer, remaining at around 16,100. In the STOXX 600, Basic Mate...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, AMADEUS, CELLNEX, IAG, SACYR. EUROPA: BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. Se mantienen las dudas Con la campaña de resultados entrando en su recta final, los principales índices europeos cerraron con pérdidas, destacando...
Coty: Q1 earnings down sharply as expected, slightly more optimistic guidance for Q2|NIH attempts risky return to primary market|Sappi: EBITDA plummets in Q4 and the situation is unlikely to improve in the short term|Worldline presents its transformation plan and plans a capital increase of € 500m|Air Baltic: a new liquidity injection seems unavoidable|
Coty : Résultats T1 en net repli comme attendu, guidance légèrement plus optimiste pour le T2|NIH tente un retour risqué sur le marché primaire|Sappi : l’EBITDA s’effondre au T4 et la situation ne devrait pas s’arranger à court-terme|Worldline présente son plan de transformation et compte réaliser une augmentation de capital de 500 m EUR|Air Baltic: a new liquidity injection seems unavoidable|
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.